ERBB2 and neoplasm: Although our sample of patients was very small, we are confident that PAR1 is an equally accurate prognostic factor for metastases and mortality as are EGFR and HER2 [21,22,24], since comparison of PAR1-positive and PAR1-negative patients revealed no significant differences in the main prognostic parameters typically considered in breast cancer (e.g., age, tumour diameter, hormonal status, etc).